Cancer Risk Concerns and Communication Gaps Regarding GLP-1 Medications
Roxanna Attar-Olyaee, Ramez Kouzy, Michael K. Rooney, Zakaria El-Kouzi, Karen E. Hoffman, Sherif M. Gadoue, Comron J. Hassanzadeh, Junyi Jessy Li, Osama Mohamad
TL;DR
This study examines what patients are saying online about cancer risks from GLP-1 medications and how much they're discussing these concerns with their doctors.
Contribution
The study provides new insights into patient concerns and communication gaps about cancer risks related to GLP-1 medications.
Findings
Patients frequently express cancer risk concerns about GLP-1 medications on social media.
There is a notable gap in communication between patients and clinicians regarding these concerns.
Abstract
This cross-sectional study analyzes social media posts to explore patient concerns and the extent of patient–clinician communication regarding cancer risks associated with glucagon-like peptide-1 (GLP-1) medications.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPatient-Provider Communication in Healthcare · Health Literacy and Information Accessibility · BRCA gene mutations in cancer